Abbott Laboratories Change in Control Agreement Extension Notification to Executive
Abbott Laboratories has notified the executive that their Change in Control (CIC) agreement, which provides financial, health, and welfare benefits in the event of a company change in control, has been extended. The agreement, previously set to expire on December 31, 2020, will now continue through December 31, 2022. No action is required from the executive to maintain participation in the agreement.
Exhibit 10.66
[Date] | | |
| | |
To: | [Executive] | |
| | |
Re: | CIC Agreement Extension | |
Abbott’s Board of Directors recently extended your Change in Control (CIC) agreement. Its term now continues through December 31, 2022. The CIC agreement provides you with financial, health and welfare benefits in the event of a Change in Control. No action is required on your part to continue participation in the CIC agreement.
You are hereby notified that your current Change in Control Agreement, which was set to expire on December 31, 2020, has been extended to December 31, 2022.
Please retain a copy of this Notification of Extension with your important records.
